Immunotherapy and Targeted Therapies in Treatment of Visceral Leishmaniasis: current status and future prospects
Visceral leishmaniasis (VL) is a vector-borne chronic infectious disease caused by the protozoan parasite Leishmania donovani or Leishmania infantum. VL is a serious public health problem, causing high morbidity and mortality in the developing world with an estimated 0.2 -0.4 million new cases each...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2014-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00296/full |
| _version_ | 1818498854501220352 |
|---|---|
| author | Om Prakash eSingh Shyam eSundar |
| author_facet | Om Prakash eSingh Shyam eSundar |
| author_sort | Om Prakash eSingh |
| collection | DOAJ |
| description | Visceral leishmaniasis (VL) is a vector-borne chronic infectious disease caused by the protozoan parasite Leishmania donovani or Leishmania infantum. VL is a serious public health problem, causing high morbidity and mortality in the developing world with an estimated 0.2 -0.4 million new cases each year. In the absence of a vaccine, chemotherapy remains the favoured option for disease control, but is limited by a narrow therapeutic index, significant toxicities, and frequently acquired resistance. Improved understanding of VL pathogenesis offers the development of immune based treatment options either alone or in combination with chemotherapy. Modulations of host immune responses include the approaches that inhibit molecular pathways, crucial for parasite growth and maintenance; and stimulate host effectors immune responses that restore the impaired effector functions. In this review, we highlight the challenges in treatment of VL with a particular emphasis on immunotherapy and targeted therapies to improve clinical outcomes. |
| first_indexed | 2024-12-10T20:21:16Z |
| format | Article |
| id | doaj.art-6a1c142b274f4df7b9fb93eb0e7c9b02 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-10T20:21:16Z |
| publishDate | 2014-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-6a1c142b274f4df7b9fb93eb0e7c9b022022-12-22T01:35:03ZengFrontiers Media S.A.Frontiers in Immunology1664-32242014-06-01510.3389/fimmu.2014.0029680389Immunotherapy and Targeted Therapies in Treatment of Visceral Leishmaniasis: current status and future prospectsOm Prakash eSingh0Shyam eSundar1Banaras Hindu UniversityBanaras Hindu UniversityVisceral leishmaniasis (VL) is a vector-borne chronic infectious disease caused by the protozoan parasite Leishmania donovani or Leishmania infantum. VL is a serious public health problem, causing high morbidity and mortality in the developing world with an estimated 0.2 -0.4 million new cases each year. In the absence of a vaccine, chemotherapy remains the favoured option for disease control, but is limited by a narrow therapeutic index, significant toxicities, and frequently acquired resistance. Improved understanding of VL pathogenesis offers the development of immune based treatment options either alone or in combination with chemotherapy. Modulations of host immune responses include the approaches that inhibit molecular pathways, crucial for parasite growth and maintenance; and stimulate host effectors immune responses that restore the impaired effector functions. In this review, we highlight the challenges in treatment of VL with a particular emphasis on immunotherapy and targeted therapies to improve clinical outcomes.http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00296/fullImmunotherapyVisceral leishmaniasisIL-10TreatmentResistanceanti-IL-10 mAb |
| spellingShingle | Om Prakash eSingh Shyam eSundar Immunotherapy and Targeted Therapies in Treatment of Visceral Leishmaniasis: current status and future prospects Frontiers in Immunology Immunotherapy Visceral leishmaniasis IL-10 Treatment Resistance anti-IL-10 mAb |
| title | Immunotherapy and Targeted Therapies in Treatment of Visceral Leishmaniasis: current status and future prospects |
| title_full | Immunotherapy and Targeted Therapies in Treatment of Visceral Leishmaniasis: current status and future prospects |
| title_fullStr | Immunotherapy and Targeted Therapies in Treatment of Visceral Leishmaniasis: current status and future prospects |
| title_full_unstemmed | Immunotherapy and Targeted Therapies in Treatment of Visceral Leishmaniasis: current status and future prospects |
| title_short | Immunotherapy and Targeted Therapies in Treatment of Visceral Leishmaniasis: current status and future prospects |
| title_sort | immunotherapy and targeted therapies in treatment of visceral leishmaniasis current status and future prospects |
| topic | Immunotherapy Visceral leishmaniasis IL-10 Treatment Resistance anti-IL-10 mAb |
| url | http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00296/full |
| work_keys_str_mv | AT omprakashesingh immunotherapyandtargetedtherapiesintreatmentofvisceralleishmaniasiscurrentstatusandfutureprospects AT shyamesundar immunotherapyandtargetedtherapiesintreatmentofvisceralleishmaniasiscurrentstatusandfutureprospects |